Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-10-10
2011-10-18
Anderson, James (Department: 1629)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
08039488
ABSTRACT:
The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Additionally, antiinflammatory drugs, such as steroids and NSAIDs can inhibit angiogenesis dependent diseases either alone or in combination with thalidomide and related compounds. Importantly, these compounds can be administered orally.
REFERENCES:
patent: 2830991 (1958-04-01), Keller et al.
patent: 3560495 (1971-02-01), Frankus
patent: 3563986 (1971-02-01), Frankus
patent: 3625946 (1971-12-01), Heinrich et al.
patent: 3705162 (1972-12-01), Graudums et al.
patent: 4552888 (1985-11-01), Koppel et al.
patent: 4808402 (1989-02-01), Leibovich et al.
patent: 4994443 (1991-02-01), Folkman et al.
patent: 5001116 (1991-03-01), Folkman et al.
patent: 5021404 (1991-06-01), Folkman et al.
patent: 5134127 (1992-07-01), Stella et al.
patent: 5260329 (1993-11-01), Mongelli et al.
patent: 5385901 (1995-01-01), Kaplan et al.
patent: 5399363 (1995-03-01), Liversidge et al.
patent: 5405855 (1995-04-01), Andrulis, Jr.
patent: 5434170 (1995-07-01), Andrulis, Jr.
patent: 5443824 (1995-08-01), Piacquadio
patent: 5502066 (1996-03-01), Heinemann
patent: 5605684 (1997-02-01), Piacquadio
patent: 5605914 (1997-02-01), Muller
patent: 5629327 (1997-05-01), D'Amato
patent: 5643915 (1997-07-01), Andrulis, Jr. et al.
patent: 5654312 (1997-08-01), Andrulis, Jr. et al.
patent: 5679696 (1997-10-01), Fenton et al.
patent: 5731325 (1998-03-01), Andrulis, Jr. et al.
patent: 6140346 (2000-10-01), Andrulis, Jr. et al.
patent: 7435745 (2008-10-01), D'Amato
patent: 1182709 (1970-03-01), None
patent: 0325199 (1989-07-01), None
patent: 0357061 (1990-03-01), None
patent: WO 91/10424 (1991-07-01), None
patent: WO 92/14455 (1992-09-01), None
patent: WO 92/18496 (1992-10-01), None
patent: WO 94/20085 (1994-09-01), None
patent: WO 95/04533 (1995-02-01), None
Gutman et al. Anticancer Research, 1996, 16:3673-3678).
Thomas et al. Current Opinion in Oncology, 2000, 12:564-573.
Stewart et al., Clin. Cancer Res., 2004, vol. 10, No. 24, pp. 8170-8176.
Cronstein, B.N. Inflammation, 1992, vol. 16, No. 5, pp. 411-423.
Tribalto et al. Leukemia Res., 1985, vol. 9, No. 8, pp. 1043-1049 (Abstract Attached).
Algire, “Vascular reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants,” J. Natl. Cancer Inst. pp. 73-85 (1945).
Allegri, “Confermata I'inefficacia della talidomides nella terapia dei tumori,” Gazzetta Medica Italiana pp. 124-127 (1964).
Ambs et al., “Interactive effects of nitric oxide and the p53 tumor suppressor gene in carcinogenesis and tumor progression,” FASEB J. 11: 443-448 (1997).
Apt, “Effect of thalidmoide on the course of experimental Chagas' Disease,” BOI. Chil. Parasitol. 20(3): 84-86 (1965).
Aronson et al., “Thalidomide-induced peripheral neuropathy. Effect of serum factor on nerve cultures,” Arch. Dermatol. 120(11): 1466-147 (1984).
Bach et al., “Studies on the possible anti-neoplastic effect of thalidomide,” ACTA PathologicaET Microbiologica Scandinavica 59-491-499 (1963).
Bach et al., “Thalidomide in cancer chemotherapy,” Lancet 1: 1271 (1963).
Bahmer. “Therapie bel lymphozytischer infiltration,” Der Hautarzt 43: 663 (1992).
Balabanova et al., “Lupus erythcrmatosus hypertrophicus et profundus,” Z. Hautkr 67(9): 812-815 (1992).
Barnes. et al., “Tumor Necrosis Factor Production in Patients with Leprosy”, Infection and Immunity. vol. 60 No. 4. pp. 1441-1446 (1992).
Barnhill. et al., “Thalidomide: Use and Possible Mode of Action in Reactional Lepromatous Leprosy and in Various other Conditions”, J. Am. Acad. Dermatol., vol. 7, No. 3. pp. 317-323-(1982).
Barnhill, R. et al., “Studies on the Anti-inflammatory Properties of Thalidomide: Effects on Polymorphonuclear Leukocytres and Monocytes”. J. A& Acad. Derm., vol. 11, No. 5, Part 1, pp. 814-819 (1984).
Barriere. H., “Traitement par la thalidomide”. La Presse Mkdicale, vol. 12. No. 15. pp. 963 (1983).
Bazzoli, et al., “The Effects of Thalidomide and Two Analogues on the Regenerating Forelimb of the Newt”, J. Embryol. Exp. Morph., vol. 41, pp. 125-135 (1977).
Beck, Jr. et al. “Vascular Development: Cellular and Molecular Regulation”, The FASEB Journal, vol. 11, pp. 365-374 (1997).
Beccerica, E., “L'approccio terapeutico al paziente anziano con artrite reumatoide”, Clin. Ter., vol. 122, pp. 289-298 (1987).
Belaube, P. et al., “Should Thalidomide be Rehabilitated?”, Sem. Hop. Paris, vol. 59, No. 45, pp. 3101-3104 (1983).
Bensinger, W.I., “Supportive Care in Marrow Transplantation”, Curr. Opin. Oncol., vol. 4, No. 4, pp. 614-623 (1992).
Bernal, et al., “Cellular Immune Effects of Thalidomide in Actinic Prurigo”, Int'l. J, of Dermat., vol. 31, No. 8, pp. 599-600 (1992).
Blair, R. et al., “Human Mast Cells Stimulate Vascular Tube Formation”, Journal of Clinical Investigation, vol. 99, No. 11, pp. 2691-2700 (1997).
Blaschke, V. et al., Chromatographische Racernattrennung von Thalidomid and teratogene Wirkung der Enantiomere, Arzneimittel Forsch./Dru,q Res., vol. 29, No. 11, pp. 1640-1642 (1979).
Bonifacino, J. et al., “A Peptide Sequence Confers Retention and Rapid Degradation in the Endoplasmic Reticulum”, Science, vol. 2, pp. 79-80 (1990).
Bonnetblanc, et al., “Thalidomide and Recurrent Aphthous Stomatitis: a Follow-up Study”, Dermatology, vol. 193, No. 4, pp. 321-323 (1996).
Boodman, S.G., “Questions About a Popular Prenatal Test”, The Washington Post (1992).
Bowers, et al., “Effect of Thalidomide on Orogenital Ulceration”, Br. Med. Journ., vol. 287, No. 6395, pp. 799-800 (1983).
Braun et al., “Thalidomide metabolite inhibits tumor cell attachment to concanavalin a coated surfaces,” Biochem. Biophys. Res. Comm. 98(4): 1029-1034 (1981).
Braun, A.G. et al., “Teratogen Metabolism,” Energy Research Abstracts, U.S. Department of Energy, Technical Information Center Office of Scientific & Technical Information, 9(8):5508:15072 (1984).
Braun, A.G. et al., “Teratogen Metabolism: Activation of Thalidomide and Thalidomide Analogues to Products that Inhibit the Attachment of Cells to Concanavalin a Coated Plastic Surfaces,” Energy Research Abstracts, U.S. Department of Energy, Technical Information Center Office of Scientific & Technical Information, 9(8):5508:15071 (1984).
Braun, A.G. et al., “Teratogen Metabolism : Activation of Thalidomide and Thalidomide Analogues to Products that Inhibit the Attachment of Cells to Concanavalin a Coated Plastic Surfaces,” Biochemical Pharmacology 33(9):1471-1477 (1984).
Braun, A.G. et al., “Teratogen Metabolism : Activation of Thalidomide and Thalidomide Analogues to Products that Inhibit the Attachment of Cells to Concanavalin a Coated Plastic Surfaces,” Revised Version, U.S. Department of Commerce, National Technical Information Services, Harvard Medical School: Boston, MA DE84006118 (1982).
Brem et al., “Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas,” J. Neurosurg. 74: 441-446 (1991).
Bressler et al.. “Clinicopathologic Correlation of occult choroidal neovascularization in age-related mascular degeneration,” Arch. Opthamol. 110: 827 (1992).
Brodthagen, “Significant response of oral aphthosis to thalidomide treatment.” J. Am. Acad. Dermaol. 13(3): 509 (1985).
Brovarone et al., “Occhio e gravidanza.” Minerva Ginecol 43: 141-167 (1991).
Browne et al., “Expression of recombinant human plasminogen and aglycoplasminogen in HeLa cells,
Anderson James
Children's Medical Center Corporation
Jones Day
LandOfFree
Methods and compositions for inhibition of angiogenesis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for inhibition of angiogenesis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for inhibition of angiogenesis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4293119